Karyopharm Therapeutics Inc. filings document the formal disclosures of a commercial-stage oncology company centered on XPOVIO (selinexor), clinical development programs, financing arrangements, and governance matters. Form 8-K reports include operating and financial results, preliminary revenue and liquidity disclosures, clinical and regulatory updates, material agreements, and capital-structure events.
The company’s SEC record also includes proxy materials for annual and special stockholder meetings, director elections, executive compensation, shareholder voting matters, and amendments to authorized share capacity. Additional filings describe private placements, common stock and warrant structures, sales under equity offering arrangements, and amendments to credit and guaranty agreements, including covenant and liquidity terms.
Karyopharm Therapeutics joint Schedule 13G filed by Ikarian Capital, LLC and Neil Shahrestani reports beneficial ownership of 5% or less of Common Stock (CUSIP 48576U205) as of 03/31/2026. The filing lists Ikarian Capital as investment manager to a fund and managed accounts and includes a Joint Filing Agreement signed on 05/15/2026.
Karyopharm Therapeutics EVP and Chief Development Officer Stuart Poulton reported a mix of equity award vesting and a related share sale. On May 13, 2026, he acquired 896 shares of common stock at $0.00 per share through earned performance-based restricted stock units tied to full enrollment of the Phase 3 XPORT-EC-042 trial. Those units vested the same day. On May 14, 2026, 403 shares were sold at $9.50 per share under a durable automatic sale instruction plan to cover withholding tax liabilities from the vesting, and the sale was not a discretionary trade. After these transactions, he directly owned 94,821 shares of common stock.
Karyopharm Therapeutics EVP & Chief Medical Officer Reshma Rangwala reported routine equity compensation activity. On May 13, she acquired 947 shares of common stock at no cost from performance-based restricted stock units that vested after certification of a Phase 3 XPORT-EC-042 enrollment milestone. On May 14, 408 shares were sold at $9.50 per share under a durable automatic sale instruction plan adopted on April 4, 2022, solely to cover withholding tax obligations upon PSU vesting. Following these transactions, she directly holds 56,829 shares of common stock.
Karyopharm Therapeutics EVP & Chief Commercial Officer Sohanya Roshan Cheng reported two transactions in common stock. On May 13, 2026, she acquired 947 shares at no cost from performance-based restricted stock units earned after a clinical enrollment milestone in the Phase 3 XPORT-EC-042 trial was certified. On May 14, 2026, she sold 324 shares at $9.50 per share in a broker-assisted transaction under a durable automatic sale instruction plan to cover withholding tax from the PSU vesting, described as non-discretionary. Following these transactions, she directly owns 107,940 shares of Karyopharm common stock.
Karyopharm Therapeutics’ Chief Accounting Officer Kristin Abate reported a small set of routine equity transactions. On May 13, 2026, she acquired 121 shares of common stock at $0.00 per share from earned performance-based restricted stock units tied to completion of enrollment in the Company’s Phase 3 XPORT-EC-042 trial, which vested that day.
On May 14, 2026, 53 shares of common stock were sold at $9.50 per share in a broker-assisted transaction executed under a durable automatic sale instruction plan adopted on May 27, 2021, solely to satisfy withholding tax obligations from the PSU vesting, and not as a discretionary trade. After these transactions, Abate directly held 23,801 shares of Karyopharm common stock.
Karyopharm Therapeutics Inc. President and CEO Richard A. Paulson reported routine equity compensation activity. On May 13, 2026, he acquired 4,920 shares of common stock at $0.00 per share from earned performance-based restricted stock units tied to a Phase 3 XPORT-EC-042 clinical milestone. These earned PSUs vested the same day.
On May 14, 2026, Paulson sold 2,203 shares of common stock at $9.50 per share in a broker-assisted transaction under a durable automatic sale instruction plan adopted on June 10, 2021. The footnote states this sale was solely to satisfy withholding tax obligations from the PSU vesting and was not a discretionary trade. After these transactions, he directly held 269,747 shares of Karyopharm common stock.
Karyopharm Therapeutics Inc. executive Mano Michael, EVP, CLO & Secretary, reported a small automatic share sale tied to a performance-based equity award. On May 13, 2026, he acquired 700 shares of common stock via earned performance-based restricted stock units (PSUs) granted in February 2024, after a clinical enrollment milestone in the Phase 3 XPORT-EC-042 trial was certified as achieved.
On May 14, 2026, 266 shares of common stock were sold at $9.50 per share in a broker-assisted transaction under a durable automatic sale instruction plan adopted on May 16, 2022, solely to cover withholding tax liability from the PSU vesting. Following these transactions, Michael directly owns 94,398 shares of Karyopharm common stock.
Karyopharm Therapeutics Inc. Schedule 13G disclosure: Acorn-affiliated investment vehicles and Anders Hove report combined beneficial ownership positions in the issuer's common stock.
Acorn Bioventures, L.P. reports 637,608 shares (2.8%); Acorn Bioventures 2, L.P. reports 880,505 shares (3.9%); Anders Hove reports 1,518,113 shares (6.7%). The percentages are calculated using 22,662,943 shares outstanding as of May 7, 2026. Signatures are dated 05/15/2026.